14 July 2023
14 July 2023
The financing round was led by Guangrun Health Industry and supported by Reichstein Biotech.
The KIT inhibitor drug programme was suspended due to adverse reactions at the minimum required dose level.
The company could lose around $1.45m if it decides to shelve the product.
While the data was promising, caution was advised due to the small sample size and population heterogeneity.
Signs and symptoms of malabsorption and stool weight are secondary endpoints of the trial.
The study is planned to be carried out across 16 countries and more than 50 sites.
With the first healthy volunteer dosed in the Phase I trial, Psycheceutical prepares for a Phase II trial with PTSD patients to test NeuroDirect topical ketamine.
ICP-189 demonstrated favourable PK, long half-life, safety, and tolerability in a dose escalation study.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
